“Global Parkinson’s Disease Treatment market will grow at a CAGR over 6.0% by 2030”, says Visiongain

23 January 2020
Pharma

Visiongain’s new report the Parkinson’s Disease Treatment Market Report 2020-2030: Forecasts by Drug Class (Carbidopa/Levodopa/ Dopamine Receptor Agonists/ Mao Inhibitors/ Comt Inhibitors/others) by Patient Care Setting (Hospitals and Clinics) plus analysis of leading companies indicates that the global Parkinson’s Disease Treatment market will grow at a CAGR over 6.0% by 2030.

It is anticipated that the global market for the treatment of disease in Parkinson will see significant growth over the forecast period. Increasing Parkinson's disease prevalence is expected to speed up this industry's growth in the near future. In addition, combination therapies that help to prolong the function of non-stop dopaminergic stimulants, gene therapy and neural transplantation are expected. This condition is a progressive neurological disorder that affects the motions of the body. Parkinson's syndrome has five stages and can influence the facial expressions, hand & leg movements of the patient as they intensify with the rise in age.

Due to the increasing prevalence of the condition, North America has the largest market share in Parkinson's disease care industry. However, the well-developed healthcare system supports the growth of the sector. Due to the presence of untapped opportunities in this area, Asia Pacific regional sector is expected to see lucrative growth over the forecast period. In addition, promoting government policies and growing R&D activities will also accelerate the growth of the industry. The disorder market for Parkinson is naturally consolidated and dominated by companies such as GlaxoSmithKline Plc., Novartis AG, Teva Pharmaceutical Industries Ltd., and Impax Laboratories, Inc. For starters, in 2016, UK-based pharmaceutical company BIAL Pharm launched opicapone (Ongentys), a new drug to improve mobility with this condition in adult patients. Certain companies in this category include, among other players, Orion Corporation, Par Pharmaceutical, Mylan N.V., Daiichi Sankyo, Cipla Inc., Wockhardt Limited, and Apotex Inc., and Salix Pharmaceuticals. It is estimated that the hospital pharmaceutical segment will account for the largest market share.

The large proportion of this segment can be attributed primarily to the availability in these facilities of a wide range of drugs and the increasing number of patient visits to hospitals. It is projected that the hospital segment will have the largest share and is predicted to expand at the fastest rate compared to the clinic segment. This market is driven mainly by robust healthcare services offered in hospitals and the prevalence in hospitals of professional neurologists. Pharmaceutical companies are designing new and improved treatments for Parkinson's disease (PD), and in Parkinson's disease therapies and other assistive therapies, there have recently been some major product launches. For starters, the amantadine extended-release capsules / Gocovri of Adamas Pharmaceuticals released in January 2018, the first medication indicated for dyskinesia produced as a result of long-term levodopa use. In addition, most multinational companies have a strong drug pipeline to cure Parkinson's disease, and the projected timeframe may be witnessing the release of a few new drugs, according to forecasts.

Carbidopa-levodopa treatment is the most effective drug for PD motor symptoms alleviation. It has been found, however, that this medication is not as active as expected. Therefore, co-therapeutic agents such as inhibitors of COMT (catechol-O-methyltransferase) and carbidopa-levodopa therapy are essential. Comtan (entacapone) and Tasmar (tolcapone) are the two most common COMT inhibitors used in the treatment of Parkinson's disease. Both of these medications are available in tablet form. Furthermore, in conjunction with carbidopa-levodopa therapy, these medicines are regularly prescribed.

Approximately 1.2 million people in the United States are expected to have Parkinson's disease by 2030, according to the National Institute of Health. It is the United States ' second most common neurodegenerative disorder. Nevertheless, there are thousands of undetected cases. The number of people suffering from Parkinson's disease as the aging population rates continue to increase. Europe is expected to show lucrative growth. High awareness of treatment, increased R&D spending, favorable regulations and policies on pharmaceutical reimbursement, the high incidence of Parkinson's disease, the rapidly growing geriatric population and potential medical pipeline products are likely to contribute to Europe's major share of the global market for Parkinson's disease care.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Plasma Therapy Market Report 2021-2031

The market is forecasted for the next ten years based on market growth within each segment of the blood plasma products. The report study aims to explore the market drivers, restraints and also market opportunities facing blood plasma product stakeholders in different geographic areas.

26 November 2020

Read

Visiongain Publishes Precision Cancer Diagnostic Test Market Report 2021-2031

Molecular diagnostics are rapidly transforming drug development and patient selection: trials with biomarkers have higher success rates than those without, and combining patients with a proven biomarker allows efficient trials to be conducted in rare cancers.

26 November 2020

Read

Visiongain Publishes Top 50 Biosimilar Drug Manufacturers 2021

Growing demand for cost-effective drugs; rising prevalence of chronic diseases; mounting investment in drug R&D by biopharmaceutical companies; new product launches and rising acceptance of biosimilars in North America region are some of the major factors that propel the biosimilars market growth.

25 November 2020

Read

Visiongain Publishes Advanced Therapy Medicinal Products (ATMP) Market Report 2021-2031

Currently, the ATMP market is at a nascent stage and is expected to flourish during near future owing to increasing research and development activities and rising use of ATMP therapy products in treatment areas with low or no alternative treatment options support the market growth

24 November 2020

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever